An injectable hydrogel for the treatment of bronchopleural fistula

Abstract

The invention discloses a novel injectable hydrogel for treating bronchopleural fistula, and its synthesis method comprises the following steps: A. Synthesis of vitamin K3-carnosine (VKCP): taking menadione and thiolactic acid respectively in In a double-necked round-bottomed flask, methanol was then added, and the mercapto-Michael addition reaction was carried out under ice-bath conditions for 2 hours, and overnight at room temperature, thereby obtaining new thiomenadione. The invention can promote cell proliferation, and the cell viability after proliferation reaches more than 95%, has no cytotoxicity, and has high safety. At the same time, VCFP has strong antibacterial properties, and can create a relatively sterile environment by killing harmful bacteria around the fistula. Accelerate tissue repair. In addition, the characteristics of targeted delivery, mechanical stability and sustained release of hydrogel will help the sustained release of growth factors, promote cell proliferation, differentiation and tissue regeneration, and strengthen the growth of new tissue. Mechanical strength, and prolong the duration of this effect.

Description

technical field [0001] The invention relates to the technical field of biomaterials, in particular to an injectable hydrogel for treating bronchopleural fistula. Background technique [0002] Bronchopleural fistula is a pathological channel formed between the trachea, bronchus at all levels, or alveoli and the pleural cavity. The morbidity after lobectomy is 0.5% to 3%, the morbidity after pneumonectomy is 2% to 20%, and the mortality rate is as high as 18% to 50%. It is one of the most serious complications of thoracic surgery. In addition, A variety of respiratory diseases can lead to the occurrence of BPF, such as pulmonary tissue degeneration, necrosis, and perforation caused by pulmonary infections such as tuberculosis and fungi, tissue necrosis, perforation caused by radiotherapy and chemotherapy in patients with lung cancer, and adult respiratory distress syndrome, malnutrition, Hypoproteinemia, diabetes and the application of steroid drugs, etc., due to the long-ter...

AI Technical Summary

Problems solved by technology

[0003] At present, the treatment options for BPF include surgery, endoscopic treatment, and conservative medical treatment. Among them, the closure of the fistula is the key, and surgical treatment is the preferred method of fistula closure. The main methods include direct closure of the stump, vascular pedicle Soft tissue flaps (such as pericardium and pectoralis) cover the bronchial stump, surgical thoracoscopic treatment, and thoracic reconstruction. With the development and popularization of bronchoscopic interventional therapy technology, bronchoscopic occlusion of BPF fistula has gradually been applied in clinic, mainly including two occlusion methods, occlusion agent (such as biological glue, autologous blood, OB glue, etc.) And occluders (such as occluder stents, bronchial plugs, atrial septal occluders, etc.), but these occlusion materials have more or less disadvantages such as poor conformability, high price, slow wound healing, etc., and there is still a lack of unified standards Therefore, in the research on BPF occlusion therapy, the selection of effective occlusion materials to meet the required shape, size, biocompatibility, tissue regeneration and mechanical stability is still a matter of biomaterial research. It is an important challenge to explore suitable occlusion materials for the endoscopic interventional treatment of BPF

Images